林普利塞通过抑制EGR1/DUSP2轴增强MUC1-Tn CAR T细胞疗效并防止耗竭
该研究针对T-ALL中CAR T细胞因靶抗原共享导致的自相残杀和耗竭问题,开发了靶向MUC1-Tn的CAR T细胞。体外和异种移植模型中MUC1-Tn CAR T细胞有效裂解T-ALL细胞,联合PI3Kδ抑制剂林普利塞可增强抗白血病疗效和持久性,减少耗竭标志物表达和终末分化细胞比例,并诱导线粒体融合和呼吸能力增强;机制上归因于林普利塞抑制DUSP2及其上游转录因子EGR1。
要点
- MUC1-Tn在T-ALL细胞系和原代患者骨髓细胞中表达,可作为CAR T靶点。
- 林普利塞联合MUC1-Tn CAR T增强抗白血病疗效和持久性,减少耗竭。
- 机制涉及抑制EGR1/DUSP2轴及诱导线粒体融合。
核心结论
- 林普利塞通过抑制EGR1/DUSP2轴增强MUC1-Tn CAR T细胞抗T-ALL疗效并防止耗竭。
研究设计与样本
- 研究在T-ALL细胞系和原代患者骨髓细胞中确认MUC1-Tn表达并开发MUC1-Tn CAR T细胞。
- 通过体外细胞毒性实验和异种移植模型评估CAR T细胞疗效及与林普利塞联合效果。
主要发现
- MUC1-Tn CAR T细胞在体外和异种移植模型中有效裂解T-ALL细胞。
- 林普利塞增强MUC1-Tn CAR T细胞的抗白血病疗效和持久性。
- 联合治疗减少T细胞耗竭标志物表达和终末分化细胞比例,再挑战时维持肿瘤控制。
- 林普利塞诱导线粒体融合并增强CAR T细胞呼吸能力。
- 持久性增强归因于林普利塞抑制DUSP2及其上游转录因子EGR1。
临床怎么用
- 提示PI3Kδ抑制剂林普利塞或可联合MUC1-Tn CAR T细胞用于T-ALL治疗以改善持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cell therapy demonstrates suboptimal efficacy in T-cell acute lymphoblastic leukemia (T-ALL), largely due to target-mediated fratricide from shared antigen expression and effector T cell exhaustion. The Mucin1-Thomsen-nouvelle (MUC1-Tn) antigen is overexpressed in various malignancies, including T-ALL. In this study, we confirmed MUC1-Tn protein expression in T-ALL cell lines and primary patient-derived bone marrow cells and subsequently developed MUC1-Tn-targeted CAR T cells. These CAR T cells effectively lysed T-ALL cells in both in vitro cytotoxicity assays and xenograft models. Given the critical role of the PI3Kδ signaling pathway in modulating T-cell function and tumor immunosuppression, we combined MUC1-Tn CAR T cells with the PI3Kδ inhibitor linperlisib. Linperlisib enhanced the anti-leukemic efficacy and persistence of MUC1-Tn CAR T cells. This was associated with reduced T cell exhaustion marker expression, decreased proportions of terminally differentiated cells, and sustained tumor control upon rechallenge. Furthermore, linperlisib induced mitochondrial fusion and enhanced respiratory capacity in CAR T cells. Mechanistically, this enhanced persistence was attributed to linperlisib-mediated suppression of Dual Specificity Phosphatase 2 (DUSP2) and its upstream transcription factor Early Growth Response 1 (EGR1).
引用
- Wei JY, Liu ZW, Lu QS, et al. Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion. Leukemia. 2026. PMID: 42399625. doi:10.1038/s41375-026-03021-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。